AURO LABORATORIES
|
AURO LABORATORIES Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 12.50 | 3.92 | 4.56 | 11.52 | 6.51 |
| CEPS(Rs) | 14.26 | 5.64 | 6.20 | 13.18 | 8.15 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 67.32 | 54.87 | 50.58 | 45.86 | 34.49 |
| Tax Rate(%) | 24.68 | 29.13 | 26.57 | 31.66 | 28.13 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 19.89 | 8.30 | 9.09 | 20.72 | 14.32 |
| EBIT Margin(%) | 20.66 | 8.05 | 9.24 | 20.21 | 14.20 |
| Pre Tax Margin(%) | 19.29 | 6.51 | 7.62 | 19.36 | 12.88 |
| PAT Margin (%) | 14.53 | 4.62 | 5.59 | 13.23 | 9.26 |
| Cash Profit Margin (%) | 16.56 | 6.65 | 7.59 | 15.14 | 11.60 |
| Performance Ratios | |||||
| ROA(%) | 11.00 | 4.40 | 5.87 | 19.34 | 12.32 |
| ROE(%) | 20.46 | 7.43 | 9.47 | 28.67 | 20.84 |
| ROCE(%) | 20.37 | 9.92 | 12.20 | 38.88 | 24.80 |
| Asset Turnover(x) | 0.76 | 0.95 | 1.05 | 1.46 | 1.33 |
| Sales/Fixed Asset(x) | 1.74 | 2.08 | 2.05 | 2.25 | 1.85 |
| Working Capital/Sales(x) | 7.75 | 3.02 | 2.95 | 2.90 | 3.71 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.57 | 0.48 | 0.49 | 0.44 | 0.54 |
| Receivable days | 87.78 | 89.77 | 75.03 | 44.00 | 59.53 |
| Inventory Days | 68.04 | 55.24 | 24.40 | 22.23 | 30.99 |
| Payable days | 121.53 | 83.56 | 59.08 | 67.05 | 73.97 |
| Valuation Parameters | |||||
| PER(x) | 12.89 | 13.95 | 21.98 | 7.04 | 4.83 |
| PCE(x) | 11.30 | 9.68 | 16.19 | 6.15 | 3.86 |
| Price/Book(x) | 2.39 | 1.00 | 1.98 | 1.77 | 0.91 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 2.33 | 0.72 | 1.26 | 0.72 | 0.39 |
| EV/Core EBITDA(x) | 10.27 | 7.13 | 11.18 | 3.26 | 2.36 |
| EV/EBIT(x) | 11.28 | 8.93 | 13.59 | 3.57 | 2.74 |
| EV/CE(x) | 1.83 | 0.94 | 1.16 | 0.93 | 0.53 |
| M Cap / Sales | 1.87 | 0.64 | 1.23 | 0.93 | 0.45 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 1.40 | 3.99 | -6.24 | 23.89 | -6.48 |
| Core EBITDA Growth(%) | 128.22 | -6.71 | -52.35 | 65.67 | -8.91 |
| EBIT Growth(%) | 160.13 | -9.37 | -57.13 | 76.27 | -10.41 |
| PAT Growth(%) | 219.09 | -14.15 | -60.38 | 77.08 | -7.84 |
| EPS Growth(%) | 219.09 | -14.15 | -60.38 | 77.08 | -7.84 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.63 | 0.19 | 0.44 | 0.11 | 0.15 |
| Current Ratio(x) | 1.29 | 1.97 | 1.86 | 3.03 | 2.93 |
| Quick Ratio(x) | 0.94 | 1.32 | 1.64 | 2.75 | 2.26 |
| Interest Cover(x) | 15.06 | 5.23 | 5.69 | 23.92 | 10.76 |
| Total Debt/Mcap(x) | 0.26 | 0.19 | 0.22 | 0.06 | 0.16 |
Compare Financial Ratios of peers of AURO LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AURO LABORATORIES | ₹138.8 Cr | -4.3% | -3.1% | 64.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹415,697.0 Cr | -2% | -0.8% | 16.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹157,449.0 Cr | -2.7% | 3.5% | 66.7% | Stock Analytics | |
| CIPLA | ₹117,778.0 Cr | 0.7% | 1.4% | 3.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,871.0 Cr | 0.1% | -8.5% | 0.7% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹97,046.2 Cr | -0.9% | -1% | 24% | Stock Analytics | |
AURO LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AURO LABORATORIES | -4.3% |
-3.1% |
64.1% |
| SENSEX | 0.2% |
-0.1% |
7.2% |
You may also like the below Video Courses
